NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00226954 2020-03-18
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181584 2013-07-11
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00039104 2013-06-05
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00490698 2013-03-18
Zoledronate With Atorvastatin in Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00181558 2010-05-10
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Massachusetts General Hospital
Phase 2 Completed
NCT00258765 2010-04-26
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Novartis
Phase 2 Terminated
NCT00636740 2009-02-20
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Merrion Pharmaceuticals, LLC
Phase 2 Completed
NCT00072930 2008-01-15
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
MedImmune LLC
Phase 2 Completed